CellMP

Cellistic (legally CellMP) is a specialized Contract Development and Manufacturing Organization (CDMO) dedicated to the advancement of induced pluripotent stem cell (iPSC) based therapies. Launched in 2022 as a dedicated business unit of Ncardia, the company provides end-to-end development and manufacturing services through its proprietary CellMP™ and Pulse™ platforms. Cellistic specializes in creating scalable, standardized processes for differentiating iPSCs into various immune cell types, including NK cells and T cells, to support the development of off-the-shelf cell therapies. The company operates a state-of-the-art, purpose-built facility in Gosselies, Belgium, designed to meet global regulatory standards for large-scale cell therapy production. By focusing exclusively on iPSC technology, Cellistic aims to overcome the consistency and scalability limitations inherent in traditional autologous and donor-derived cell therapy manufacturing.